NCT03479476View on ClinicalTrials.gov

A Trial of Metformin in Individuals With Fragile X Syndrome

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

April 30, 2018

Primary Completion Date

May 22, 2024

Study Completion Date

May 22, 2024

Conditions
Fragile X SyndromeFragile X Mental Retardation SyndromeMental Retardation, X LinkedGenetic Diseases, X-LinkedTrinucleotide Repeat ExpansionFra(X) SyndromeIntellectual DisabilityFXSNeurobehavioral ManifestationsSex Chromosome Disorders
Interventions
DRUG

Placebo Medication

Placebo liquid or capsules given in parallel to active medication.

DRUG

Metformin

Active medication.

Trial Locations (3)

95817

UC Davis MIND Institute, Sacramento

T6G2R3

University of Alberta, Edmonton

H3T 1C5

St Justine Hospital, Montreal

All Listed Sponsors
collaborator

University of Alberta

OTHER

collaborator

St. Justine's Hospital

OTHER

lead

University of California, Davis

OTHER

NCT03479476 - A Trial of Metformin in Individuals With Fragile X Syndrome | Biotech Hunter | Biotech Hunter